Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan maintains a Buy rating on Travere Therapeutics but lowers the price target from $25 to $23.
September 27, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Guggenheim's analyst Vamil Divan continues to recommend buying Travere Therapeutics stock, but has adjusted the price target downwards from $25 to $23.
The Buy rating suggests confidence in the stock's potential, but the lowered price target indicates a tempered outlook on its short-term price appreciation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100